Prothena Corporation plc (PRTA)

NASDAQ
51.01
+2.29(+4.70%)
After Hours
51.01
0.00(0.00%)
- Real-time Data
  • Volume:
    1,131,750
  • Bid/Ask:
    50.30/53.70
  • Day's Range:
    48.86 - 53.28

PRTA Overview

Prev. Close
51.01
Day's Range
48.86-53.28
Revenue
880K
Open
49.52
52 wk Range
9.39-59.37
EPS
-3.11
Volume
1,131,750
Market Cap
2.25B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
439,702
P/E Ratio
-
Beta
1.37
1-Year Change
414.73%
Shares Outstanding
44,175,792
Next Earnings Date
Aug 10, 2021
What is your sentiment on Prothena Corporation plc?
or
Market is currently closed. Voting is open during market hours.

Prothena Corporation plc News

Prothena Corporation plc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyBuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Prothena Corporation plc Company Profile

Prothena Corporation plc Company Profile

Employees
66

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson’s disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer’s disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Read More
  • 🚀
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.